43 trials changed in the last 30 days: 1 stopped, 17 with notable changes, 25 with minor changes only.
Trial terminated
Also in this update: Final enrollment: 14 participants (planned 135)
Boehringer IngelheimPhase 1 NCT06882746 Registry history of NCT06882746 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 1, 2027 to Mar 1, 2028
Also in this update: Study completion pushed from Sep 29, 2027 to Mar 29, 2028
Boehringer IngelheimPhase 2 NCT06962839 Registry history of NCT06962839 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Boehringer IngelheimPhase 1 NCT04886804 Registry history of NCT04886804 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Interventions modified
Boehringer IngelheimPhase 1 NCT07837648 Registry history of NCT07837648 on ClinicalTrials.gov (opens the registry)
Enrollment reopened
Boehringer IngelheimPhase 2 NCT06321302 Registry history of NCT06321302 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Oct 5, 2026 to Oct 1, 2026; and 1 more change in the last 30 days
Boehringer IngelheimPhase 1/2 NCT07843940 Registry history of NCT07843940 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Boehringer IngelheimPhase 1 NCT07845630 Registry history of NCT07845630 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 163 → 166 locations; and 2 more changes in the last 30 days
Boehringer IngelheimPhase 3 NCT07540988 Registry history of NCT07540988 on ClinicalTrials.gov (opens the registry)
Suspended trial terminated
Boehringer IngelheimPhase 1 NCT07656792 Registry history of NCT07656792 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Boehringer IngelheimPhase 1 NCT07781631 Registry history of NCT07781631 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Boehringer IngelheimPhase 1 NCT07754474 Registry history of NCT07754474 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date pushed from Sep 7, 2026 to Sep 21, 2026
Boehringer IngelheimPhase 1 NCT07744152 Registry history of NCT07744152 on ClinicalTrials.gov (opens the registry)
Start date pushed from May 6, 2024 to Sep 26, 2024
And 1 more change in the last 30 days
Boehringer IngelheimPhase 3 NCT06238622 Registry history of NCT06238622 on ClinicalTrials.gov (opens the registry)
Start date pushed from Nov 9, 2026 to Dec 14, 2026
Boehringer IngelheimPhase 3 NCT07789015 Registry history of NCT07789015 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 14, 2026
Boehringer IngelheimPhase 2 NCT05512377 Registry history of NCT05512377 on ClinicalTrials.gov (opens the registry)
Primary and study completion moved earlier from Aug 30, 2028 to Dec 31, 2026
Also in this update: Enrollment closed, study ongoing; and 2 more changes in the last 30 days
Boehringer IngelheimPhase 3 NCT06531824 Registry history of NCT06531824 on ClinicalTrials.gov (opens the registry)
Results posted: Sep 23, 2026
Boehringer IngelheimPhase 2 NCT06360094 Registry history of NCT06360094 on ClinicalTrials.gov (opens the registry)
Primary completion moved earlier from Mar 31, 2028 to Mar 31, 2027
Also in this update: Study completion moved earlier from Apr 30, 2028 to Apr 30, 2027
Boehringer IngelheimPhase 1 NCT04111458 Registry history of NCT04111458 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 135 participants (planned 120)
Boehringer IngelheimPhase 3 NCT07107945 Registry history of NCT07107945 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Boehringer IngelheimPhase 1 NCT07774325 Registry history of NCT07774325 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 122 participants (planned 100)
Boehringer IngelheimNot specified NCT07743996 Registry history of NCT07743996 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 81 participants (planned 71)
Boehringer IngelheimPhase 2 NCT07036523 Registry history of NCT07036523 on ClinicalTrials.gov (opens the registry)
Trial completed
Boehringer IngelheimPhase 1 NCT07526194 Registry history of NCT07526194 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Boehringer IngelheimPhase 1 NCT07708493 Registry history of NCT07708493 on ClinicalTrials.gov (opens the registry)
Trial completed
Boehringer IngelheimPhase 1 NCT07727785 Registry history of NCT07727785 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Boehringer IngelheimPhase 1 NCT07693231 Registry history of NCT07693231 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 30, 2026 to Dec 15, 2026
Boehringer IngelheimPhase 1 NCT05963867 Registry history of NCT05963867 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 23, 2026 to Nov 30, 2026
And 2 more changes in the last 30 days
Boehringer IngelheimNot specified NCT05882071 Registry history of NCT05882071 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 2, 2026 to Dec 10, 2026
Boehringer IngelheimPhase 3 NCT06151574 Registry history of NCT06151574 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 25 locations
Boehringer IngelheimPhase 3 NCT07850063 Registry history of NCT07850063 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 585 → 594 locations
And 1 more change in the last 30 days
Boehringer IngelheimPhase 3 NCT06935370 Registry history of NCT06935370 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 311 → 316 locations
And 1 more change in the last 30 days
Boehringer IngelheimPhase 3 NCT07220083 Registry history of NCT07220083 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 13 locations
Boehringer IngelheimPhase 3 NCT07850050 Registry history of NCT07850050 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 164 → 159 locations
Boehringer IngelheimPhase 2 NCT07355296 Registry history of NCT07355296 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 16 → 20 locations
And 1 more change in the last 30 days
Boehringer IngelheimPhase 1 NCT05471856 Registry history of NCT05471856 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 471 → 478 locations
Boehringer IngelheimPhase 3 NCT06872892 Registry history of NCT06872892 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 653 → 664 locations
And 1 more change in the last 30 days
Boehringer IngelheimPhase 3 NCT06424288 Registry history of NCT06424288 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Jul 30, 2027 to Apr 28, 2027
Also in this update: Primary completion moved earlier from Jul 17, 2027 to Apr 15, 2027; and 1 more change in the last 30 days
Boehringer IngelheimPhase 3 NCT06806592 Registry history of NCT06806592 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Mar 11, 2031 to Dec 13, 2029
Boehringer IngelheimPhase 3 NCT07544654 Registry history of NCT07544654 on ClinicalTrials.gov (opens the registry)
Start date moved earlier from Apr 13, 2026 to Nov 7, 2025
Boehringer IngelheimPhase 3 NCT07472517 Registry history of NCT07472517 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Aug 18, 2027 to Jul 10, 2027
Also in this update: Primary completion moved earlier from Aug 4, 2027 to Jun 26, 2027
Boehringer IngelheimPhase 2 NCT07662122 Registry history of NCT07662122 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 29, 2026 to Oct 19, 2026
Boehringer IngelheimPhase 1/2 NCT07707895 Registry history of NCT07707895 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Jul 14, 2027 to Nov 25, 2026
Boehringer IngelheimPhase 1 NCT05068102 Registry history of NCT05068102 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-02 | NCT07855900 SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With… | Phase 3 | Not Yet Recruiting |
| 2026-10-01 | NCT07851103 A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in… | Phase 1 | Not Yet Recruiting |
| 2026-09-30 | NCT07850050 SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With… | Phase 3 | Not Yet Recruiting |
| 2026-09-30 | NCT07850063 ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and… | Phase 3 | Not Yet Recruiting |
| 2026-09-29 | NCT07845630 A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat /… | Phase 1 | Recruiting |
| 2026-09-28 | NCT07843940 A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small… | Phase 1/2 | Recruiting |
| 2026-09-23 | NCT07837648 A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in… | Phase 1 | Recruiting |
| Phase 1 | 40 | |
| Phase 1/2 | 5 | |
| Phase 2 | 15 | |
| Phase 3 | 25 |
Lung Cancer (15) · Obesity (10) · Small Cell Lung Cancer (9) · Non-Small Cell Lung Cancer (NSCLC) (6) · Heart Disease (5) · Chronic Kidney Disease (4) · Diabetes (4) · Heart Failure (4) · NASH / MASH (4) · Type 2 Diabetes (3)